Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Methyl ester with preset stereochemistry
What ifWhat if the process starts with the methyl ester of the (2S,4R) acylated pyrrolidine?
The methyl ester enters the process with the target configuration at both ring stereocenters. Aqueous sodium hydroxide hydrolyzes the methyl ester at ambient temperature to give the sodium carboxylate and methanol.
1.1Dry acid cleavage of ester
What ifWhat if a dry organic medium serves for ester cleavage after the ring stereochemistry is set?
Claim language“a solvent and water”
The (2S,4R) tert-butyl ester undergoes acidolysis with trifluoroacetic acid in dry dichloromethane to give the free carboxylic acid. After removal of the volatile acid and solvent, sodium methoxide in dry methanol converts the free acid to the sodium carboxylate.
1.2Sodium supplied by ion exchange
What ifWhat if an organic hydroxide cleaves the ester and an ion exchange resin supplies sodium?
Claim language“adding a base comprising M+”
Aqueous tetrabutylammonium hydroxide hydrolyzes the methyl ester of the (2S,4R) compound to the tetrabutylammonium carboxylate. A strong-acid cation exchange resin in sodium form retains tetrabutylammonium and releases sodium into the carboxylate solution.
1.2Calcium carboxylate formation
What ifWhat if calcium serves as the counterion for the carboxylate?
Claim language“M+ is selected from Li+, Na+ and K+”
Calcium carbonate neutralizes the free carboxylic acid in an aqueous alcohol, releasing carbon dioxide. The resulting salt contains two carboxylate anions per calcium ion.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Stereochemical standards for analytical laboratories
An analytical laboratory uses the conversion to prepare a reference material for measuring stereoisomer content. A stirred vial holds the (2R,4R) tert-butyl ester, solvent, and water before addition of a potassium base. The laboratory monitors formation of the (2S,4R) ester and its conversion to the potassium carboxylate by liquid chromatography. The laboratory isolates the salt, assigns its content by quantitative nuclear magnetic resonance, and uses it to prepare calibration solutions.
Component substitution
Sodium hydroxide in a stirred batch
Sodium hydroxide replaces the alkoxide base and supplies the sodium counterion. A stirred reactor holds the (2R,4R) tert-butyl ester, tetrahydrofuran, and water, and a feed line meters aqueous sodium hydroxide into the mixture. Liquid chromatography tracks the starting ester, the (2S,4R) ester intermediate, and both carboxylate stereoisomers. The batch endpoint uses the measured concentrations of these species to determine when to cool the mixture and recover the sodium carboxylate.
Parameter or scale variation
Parallel batches with timed base addition
Eight stirred 20 mL vials each receive a 5 mL charge containing the (2R,4R) tert-butyl ester, solvent, and water. The vials run in duplicate at base addition times of 2, 5, 10, and 20 minutes, with the same total base charge, temperature, and stirring speed. Samples taken at 5, 15, 30, and 60 minutes after each addition ends provide concentration profiles for the starting ester, the epimerized ester, and the carboxylate. The profiles show how feed duration changes intermediate accumulation and the time to the carboxylate endpoint.
Combination with existing systems
Membrane concentration after batch conversion
A stirred batch reactor performs base addition, epimerization, and conversion to the alkali metal carboxylate. After conversion, reduced-pressure stripping lowers the organic solvent content, and a cartridge filter removes suspended solids from the aqueous product stream. A crossflow nanofiltration skid recirculates the clarified stream through a membrane selected by measuring carboxylate retention and permeate flux at the workup pH. The retentate collects the carboxylate in a smaller aqueous volume for downstream isolation.
Stirred reactor cascade for continuous conversion
A feed vessel holds a stirred mixture of the (2R,4R) tert-butyl ester, solvent, and water, and a separate vessel supplies the alkali metal base. Metering pumps deliver both streams to the first of two jacketed stirred tanks connected in series. The first tank provides residence time for epimerization, and the second provides additional residence time for conversion of the (2S,4R) ester to the carboxylate salt. Sampling ports on both outlets provide composition data for setting feed rates, liquid levels, and jacket temperatures.
Automated or data-driven variant
Chromatographic control of batch endpoint
An automated sampling valve transfers aliquots from the stirred reactor to a dilution and quench station connected to a liquid chromatograph. The chromatographic method resolves the two tert-butyl ester stereoisomers and the two carboxylate stereoisomers, and the controller calculates their concentrations from calibrated peak areas. The controller maintains the reaction temperature until two successive samples meet preset limits for residual ester and undesired carboxylate. It then starts jacket cooling and records the chromatograms and batch endpoint.
Specific version of a part
Aqueous dioxane charge
Compound 4 is dissolved in 1,4-dioxane and combined with water before base addition. Agitation distributes the water throughout the ester solution.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1the steps of a) combining tert-butyl (2R,4R)-1-{(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-(trifluoromethyl)pyrrolidine-2-carboxylate (Compound 4) a solvent and water
A suspension of {[2-(tert-butoxycarbonyl-methyl-amino)-acetyl]-methyl-amino}-acetic acid ethyl ester (12.3 g, 42.7 mmol) and LiOH (8.9 g, 214 mmol) in H2O (20 mL) and THF (100 mL) was stirred overnight.
A · US 2013/0165442 A1 · ¶ 465
1.2b) adding a base comprising M+ to the mixture from step a) to generate intermediate tert-Butyl (2S,4R)-1-{(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-(trifluoromethyl)pyrrolidine-2-carboxylate, Compound 5, in situ which further reacts to provide the (2S,4R)-1-{(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-(trifluoromethyl)pyrrolidine-2-carboxylate M+ salt, Compound 6a wherein M+ is selected from Li+, Na+ and K+.
Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
B · US 8,614,180 B2 · ¶ 91
An empty cell means only that no passage was reproduced there.
Statements in these documents
The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
A · US 2013/0165442 A1 · ¶ 2
In patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport.
A · US 2013/0165442 A1 · ¶ 7
Certain 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication.
B · US 8,614,180 B2 · ¶ 2
Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide and one or more other pharmaceutically active agents.
B · US 8,614,180 B2 · ¶ 2
Cite aspatent.fyi, US 2026/0356799 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356799/, SHA-256 15ac5f6ea4464e5c71c1fc05fb7879c45bd1eccdd1b239bdcc29331d92705d0a